210 related articles for article (PubMed ID: 31064887)
1. Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an
Guan Y; Song Z; Li Y; Guo H; Shi J; Zhang X; Yao M
Oncologist; 2019 Aug; 24(8):1027-1030. PubMed ID: 31064887
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
3. EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
Zhu YC; Wang WX; Xu CW; Song ZB; Du KQ; Chen G; Lv TF; Song Y
Lung Cancer; 2018 Jan; 115():131-134. PubMed ID: 29290255
[TBL] [Abstract][Full Text] [Related]
4. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
[TBL] [Abstract][Full Text] [Related]
5. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Xu L; Qi Q; Zhang Y; Cui J; Liu R; Li Y
Lung Cancer; 2019 Jul; 133():23-31. PubMed ID: 31200823
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
Liang S; Wang H; Zhang Y; Tian H; Li C; Hua D
Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
[TBL] [Abstract][Full Text] [Related]
8. Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
Heng W; You C; Shangli C; Chuang Q; Mingzhe X
Lung Cancer; 2019 Oct; 136():153-155. PubMed ID: 31422893
[No Abstract] [Full Text] [Related]
9. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
10. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
[TBL] [Abstract][Full Text] [Related]
11. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
13. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
14. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
15. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Wang J; Chen J
BMC Cancer; 2019 Feb; 19(1):131. PubMed ID: 30736738
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
[TBL] [Abstract][Full Text] [Related]
17. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
[TBL] [Abstract][Full Text] [Related]
18. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Jin LL; Wu ZZ; Wang YL; Chen DS; Li S; Xiao M; Zhao X
Invest New Drugs; 2021 Oct; 39(5):1419-1421. PubMed ID: 33835358
[TBL] [Abstract][Full Text] [Related]
19. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
